The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this clinical trial is to determine whether long-term oral dosage of
ribavirin delays development of symptomatic HIV disease in HIV antibody positive subjects who
are completely asymptomatic (CDC classification group II), who have only the lymphadenopathy
syndrome (CDC classification group III), or who have clinical symptoms but not severe HIV
disease as defined by CDC classification, and whether the dosage regimen is safe and
tolerable in these subjects.